Develops drug candidates that target immune-cell proteins for people with cancers and immune-mediated and inflammatory diseases.
10-K for FY2025, filed Mar 12, 2026
No revenue reported yet.
10-K for FY2025, filed Mar 12, 2026
10-Q for Q3 FY2026, filed Nov 5, 2026
−$20.3MView ↗
Competes with Abbvie, Pfizer, Sanofi, Amgen, GSK, Lilly, Arcus Biosciences, and AstraZeneca
10-K for FY2025, filed Mar 12, 2026Soquelitinib is an investigational oral therapy in development for the treatment of immune diseases and cancer. Soquelitinib is designed to…View ↗
Loading...